Cyclophosphamide
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Cyclophosphamide. The intravenous regime is administered in weekly or monthly pulses. Fully referenced neurology checklist.
Dosing
- The intravenous regime is administered in weekly or monthly pulses
- The oral regime is administered qid
- The intravenous route has less toxicity
Precautions
Locked: subscribe to see this section.
Contraindications
Locked: subscribe to see this section.
Monitoring
Locked: subscribe to see this section.
Adverse events
Locked: subscribe to see this section.
Indications for stopping
Locked: subscribe to see this section.
References
- Amato AA, Russell JA. Neuromuscular Disorders. McGraw Hill New York 2008 p711.
- Teles KA, Medeiros-Souza P, Lima FAC, Araújo BG, Lima RAC. Cyclophosphamide administration routine in autoimmune rheumatic diseases: a review. Rev Bras Reumatol Engl Ed 2017; 57:596-604.
- Lapraik C, Watts R, Bacon P, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology 2007; 46: 1615-1616.
- Malpica L, Moll S. Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases. Hematology Am Soc Hematol Educ Program 2020; 2020:319-327.
- Abrantes FF, Moraes MPM, Albuquerque Filho JMV, et al. Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy. Arq Neuropsiquiatr 2021; 79:1012-1025.
- And 1 more. Subscribe to see the full list
